CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced the formation of a Corporate Advisory Board to provide expert insight and contribute to the Company’s corporate strategy and product development plans. The formation of the Corporate Advisory Board comes at a time when X4 is initiating clinical development of X4P-001, its lead drug candidate in refractory clear cell renal cell carcinoma (ccRCC). X4 expects to initiate a second clinical study for X4P-001 in another solid tumor indication later this year.
